<DOC>
	<DOCNO>NCT00945490</DOCNO>
	<brief_summary>This study evaluate safety efficacy 2.5 mg dose NX-1207 treatment BPH ( benign prostatic hyperplasia ) compare placebo .</brief_summary>
	<brief_title>Clinical Evaluation NX-1207 Treatment Benign Prostatic Hyperplasia ( BPH ) NX02-0018</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>1 . Provide sign informed consent prior enrolment study 2 . AUASI ≥ 15 3 . Prostate Volume ≥ 30 mL ≤ 70 mL 4 . Qmax &lt; 15 mL/sec base minimum void 125 mL 5 . Agree use approve experimental BPH OAB medication anytime study 1 . History illness condition may interfere study endanger subject 2 . Use prescribed medication may interfere study endanger subject 3 . Presence median lobe prostate 4 . Previous surgery MIST treatment BPH 5 . Postvoid residual urine volume &gt; 200 mL 6 . PSA ≥ 10 ng/mL ; prostate cancer must rule ( negative biopsy ) PSA ≥ 4 ng/mL 7 . Participation study investigational drug device within previous 90 day 8 . Prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged prostate</keyword>
</DOC>